Loading...
The ALK project: a real-world national network and database
Gomes, Fabio Yip, K. Tokaca, N. Greystoke, A. Escriu, C. Conibear, J. Ghosh, S. Doherty, G. J. Funingana, I. Ahmad, T.
Gomes, Fabio
Yip, K.
Tokaca, N.
Greystoke, A.
Escriu, C.
Conibear, J.
Ghosh, S.
Doherty, G. J.
Funingana, I.
Ahmad, T.
Citations
Altmetric:
Abstract
Introduction: NSCLC patients with ALK translocation are rare,
accounting for 1600 cases/year in England. Our group established
an ALK network across the UK with the aim to analyse treatment
patterns/outcomes, promote research and establish a collaborative
network.
Methods: As part of this active project and expanding network,
we conducted a multicentre retrospective analysis across 23 NHS
England trusts on ALK+ patients who were offered treatment
until Sept-2018 with any of the newer generation ALK inhibitors
(ceritinib, alectinib, brigatinib and lorlatinib). The primary aim
of this study was overall survival (OS). The secondary aims were
analysing treatment patterns, treatment exposure times (surrogate
of clinical benefit) and objective response rates (ORR).
Results: A total of 181 patient files were included in the ALK Project
database by Sept-2018, of which 132 received a newer generation
ALK inhibitor. 87% had advanced/metastatic disease at diagnosis with
a median age of 53 years, being 54% females and 69% never smokers.
The median OS was 6.2 years (95% CI, 4.9-7.4). Median OS was not
reached for the 48% of patients with no known brain metastasis. 45%
of patients received chemotherapy prior to an ALK inhibitor, 12% of
which after the approval of 1st line ALK inhibitors. 6% of patients
received immunotherapy, of which only 1 patient achieved disease
control. On average patients received 3 lines of treatment, having
received ceritinib (63%), brigatinib (37%), alectinib (21%) and/or
lorlatinib (14%). The exposure times and ORRs per drug are available
in Table 1. Reassessment of genomic profile during therapy with ALK
inhibitors was performed in 10% of cases. Conclusion: Big real-world data is vital for rare diseases subtypes.
A nationwide collaboration is possible and should be promoted.
The remarkable survival of these patients mirrors the revolution in
their treatment landscape. All efforts should be done to exclude ALK
rearrangement, particular in never smokers.
Authors
Gomes, Fabio
Yip, K.
Tokaca, N.
Greystoke, A.
Escriu, C.
Conibear, J.
Ghosh, S.
Doherty, G. J.
Funingana, I.
Ahmad, T.
Ahmed, S.
Cox, R. A.
Newsom-Davis, T.
Mills, H.
Shah, R.
Dorey, N.
Harle, A.
Dancey, G.
Baijal, S.
Geldart, T.
Ghafoor, Q.
Tarver, K.
Talbot, T.
Forster, M.
Cove-Smith, Laura
Califano, Raffaele
Blackhall, Fiona H
Popat, S.
Summers, Yvonne J
Yip, K.
Tokaca, N.
Greystoke, A.
Escriu, C.
Conibear, J.
Ghosh, S.
Doherty, G. J.
Funingana, I.
Ahmad, T.
Ahmed, S.
Cox, R. A.
Newsom-Davis, T.
Mills, H.
Shah, R.
Dorey, N.
Harle, A.
Dancey, G.
Baijal, S.
Geldart, T.
Ghafoor, Q.
Tarver, K.
Talbot, T.
Forster, M.
Cove-Smith, Laura
Califano, Raffaele
Blackhall, Fiona H
Popat, S.
Summers, Yvonne J
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Gomes F, Yip K, Tokaca N, Greystoke A, Escriu C, Conibear J, et al. The ALK project: a real-world national network and database. Lung Cancer. 2019;127:S31-S2.